Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors

Elenagen is a plasmid encoding p62/SQSTM1, the first DNA vaccine possessing two mutually complementing mechanisms of action: it elicits immune response against p62 and mitigates systemic chronic inflammation. Previously, Elenagen demonstrated anti-tumor efficacy and safety in rodent tumor models and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ponomarenko, Dmitry M., Klimova, Irina D., Chapygina, Yulia A., Dvornichenko, Viktoria V., Zhukova, Natalia V., Orlova, Rashida V., Manikhas, Georgy M., Zyryanov, Alexandr V., Burkhanova, Lilya A., Badrtdinova, Irina I., Oshchepkov, Basile N., Filippova, Elena V., Orlov, Sergei V., Kolesnikov, Sergei I., Sufianov, Albert A., Baum, Svetlana R., Zaitzeva, Olga Y., Komissarov, Andrey B., Grudinin, Mikhail P., Kiselev, Oleg I., Tsyb, Anatoly F., Venanzi, Franco, Shcherbinina, Vita, Chursov, Andrey, Gabai, Vladimir L., Shneider, Alexander M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581145/
https://www.ncbi.nlm.nih.gov/pubmed/28881846
http://dx.doi.org/10.18632/oncotarget.16574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581145/
https://www.ncbi.nlm.nih.gov/pubmed/28881846
http://dx.doi.org/10.18632/oncotarget.16574

Ejemplares similares